Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Operating Leases (2019 - 2025)

Editas Medicine (EDIT) has disclosed Operating Leases for 7 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 38.61% to $13.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.6 million, a 38.61% decrease, with the full-year FY2024 number at $20.4 million, down 16.38% from a year prior.
  • Operating Leases was $13.6 million for Q3 2025 at Editas Medicine, down from $15.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $32.9 million in Q4 2022 to a low of $9.3 million in Q3 2022.
  • A 5-year average of $19.9 million and a median of $20.5 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 52.5% in 2022, then surged 167.13% in 2023.
  • Editas Medicine's Operating Leases stood at $16.1 million in 2021, then skyrocketed by 104.52% to $32.9 million in 2022, then fell by 25.84% to $24.4 million in 2023, then dropped by 16.38% to $20.4 million in 2024, then plummeted by 33.44% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Operating Leases are $13.6 million (Q3 2025), $15.0 million (Q2 2025), and $18.0 million (Q1 2025).